All In Biotech

NDA 200327 · Abbvie

Teflaro

Ceftaroline Fosamil · Intravenous

Novel

Last checked: Nov 19, 2026Latest source record: Dec 2, 2021 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2010

Oct 29, 2010

Approved uses

6

Original approval plus efficacy supplements

Registered trials

47

13 Phase 3, 2 recruiting

FAERS reports

839

679 serious, 154 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Nov 20, 2024.

1. INDICATIONS AND USAGE Teflaro is a cephalosporin antibacterial indicated in adult and pediatric patients for the treatment of the following infection caused by designated susceptible bacteria: Acute bacterial skin and skin structure infections (ABSSSI) in adult and pediatric patients (at least 34 weeks gestational age and 12 days postnatal age) ( 1.1 ) Community-acquired bacterial pneumonia (CABP) in adult and pediatric patients 2 months of age and older ( 1.2 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of Teflaro and other antibacterial drugs, Teflaro should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.3 ) 1.1 Acute Bacterial Skin and Skin Structure Infections Teflaro is indicated in adult and pediatric patients (at least 34 weeks gestational age and 12 days postnatal age) for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive and Gram-negative microorganisms: Staphylococcus aureus (including methicillin-susceptible and -resistant isolates), Streptococcus pyogenes , Streptococcus agalactiae , Escherichia coli , Klebsiella pneumoniae , and Klebsiella oxytoca [see Dosage and Administration ( 2.2 ) and Use in Specific Populations ( 8.4 )] . 1.2 Community-Acquired Bacterial Pneumonia Teflaro is indicated in adult and pediatric patients 2 months of age and older for the treatment of community-acquired bacterial pneumonia (CABP) caused by susceptible isolates of the following Gram-positive and Gram-negative microorganisms: Streptococcus pneumoniae (including cases with concurrent bacteremia), Staphylococcus aureus (methicillin-susceptible isolates only), Haemophilus influenzae,...

Mechanism: Ceftaroline is a cephalosporin antibacterial drug [ see Microbiology ( 12.4 )] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

2 products under this application
  • TEFLARO · CEFTAROLINE FOSAMIL 600MG/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP
  • TEFLARO · CEFTAROLINE FOSAMIL 400MG/VIAL · POWDER, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Ceftaroline Fosamil" as an intervention, any sponsor and status, largest first.

All 47 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use141
  • neutropenia77
  • drug ineffective64
  • acute kidney injury52
  • death48
  • rash46
  • agranulocytosis40
  • thrombocytopenia37
  • pyrexia34
  • drug reaction with eosinophilia and systemic symptoms33
  • renal failure31
  • pruritus29

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
201115
201229
201353
201471
201537
201649
201730
201845
201953
202042
202159
202234
202362
202485
202578
202697

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Teflaro (Ceftaroline Fosamil Acetate)

2024 spending

$12.5M

Beneficiaries

929

4,467 claims

Per beneficiary

$13,509

$45.07 per unit

View as table
YearSpending
2020$11,106,086
2021$10,145,910
2022$11,329,226
2023$11,267,093
2024$12,549,725

Part B: Teflaro (Ceftaroline Fosamil Acetate) · HCPCS J0712

2024 spending

$231K

Beneficiaries

115

592 claims

Per beneficiary

$2,008

2024 ASP limit $3.91 per unit

View as table
YearSpending
2020$526,180
2021$474,880
2022$369,311
2023$332,769
2024$230,930

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 44 on PubMed

Sponsor: AbbVie

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.